About IDEXX Laboratories (NASDAQ:IDXX)
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Veterinary Medical Equipment & Supplies
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:IDXX
- CUSIP: 45168D10
- Web: www.idexx.com
- Market Cap: $14.37523 billion
- Outstanding Shares: 87,275,000
- 50 Day Moving Avg: $158.19
- 200 Day Moving Avg: $160.18
- 52 Week Range: $102.45 - $173.01
Sales & Book Value:
- Trailing P/E Ratio: 56.66
- Foreward P/E Ratio: 46.27
- P/E Growth: 2.69
- Annual Revenue: $1.86 billion
- Price / Sales: 7.73
- Book Value: ($0.99) per share
- Price / Book: -166.37
- EBITDA: $467.99 million
- Net Margins: 14.13%
- Return on Equity: -473.46%
- Return on Assets: 16.18%
- Debt-to-Equity Ratio: -6.98%
- Current Ratio: 0.92%
- Quick Ratio: 0.75%
- Average Volume: 494,214 shs.
- Beta: 0.48
- Short Ratio: 4.18
Frequently Asked Questions for IDEXX Laboratories (NASDAQ:IDXX)
What is IDEXX Laboratories' stock symbol?
IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
How will IDEXX Laboratories' stock buyback program work?
IDEXX Laboratories announced that its Board of Directors has approved a share buyback plan on Sunday, June 4th 2017, which allows the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's management believes its stock is undervalued.
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings results on Tuesday, August, 1st. The company reported $0.95 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.85 by $0.10. The business had revenue of $508.90 million for the quarter, compared to the consensus estimate of $502.44 million. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. IDEXX Laboratories's revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business posted $0.74 EPS. View IDEXX Laboratories' Earnings History.
When will IDEXX Laboratories make its next earnings announcement?
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories updated its FY17 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $3.12-3.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.07. The company issued revenue guidance of $1.945-1.965 billion, compared to the consensus revenue estimate of $1.94 billion.
Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2017?
6 equities research analysts have issued twelve-month price targets for IDEXX Laboratories' shares. Their predictions range from $118.00 to $200.00. On average, they anticipate IDEXX Laboratories' share price to reach $171.60 in the next year. View Analyst Ratings for IDEXX Laboratories.
What are analysts saying about IDEXX Laboratories stock?
Here are some recent quotes from research analysts about IDEXX Laboratories stock:
- 1. According to Zacks Investment Research, "Over the last six months, IDEXX has been trading below the broader industry. Also, the company’s high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation is also a concern. On a positive note, IDEXX continues to demonstrate solid growth globally on strong international expansion. Management’s innovation-based global strategy is leading to CAG Diagnostics growth. Notably, IDEXX recently widened its cloud technology portfolio by adding rVetLink. Solid organic revenue growth along with a raised guidance for 2017 buoy optimism." (10/18/2017)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)
Who are some of IDEXX Laboratories' key competitors?
Some companies that are related to IDEXX Laboratories include Astellas Pharma (ALPMY), Essilor International SA (ESLOY), Zimmer Biomet Holdings (ZBH), Cerner Corporation (CERN), Incyte Corporation (INCY), C.R. Bard (BCR), Edwards Lifesciences Corporation (EW), Quintiles Transitional Holdings (Q), Cardinal Health (CAH), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Smith & Nephew SNATS (SNN), Centene Corporation (CNC), Align Technology (ALGN), Lonza Group Ag (LZAGY), Laboratory Corporation of America Holdings (LH), BioMarin Pharmaceutical (BMRN) and Eisai Co., Ltd (ESALY).
Who are IDEXX Laboratories' key executives?
IDEXX Laboratories' management team includes the folowing people:
- Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer
- Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer
- Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
- Jay Mazelsky, Executive Vice President
- Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary
- William T. End, Lead Independent Director
- Bruce L. Claflin, Independent Director
- Stuart M. Essig Ph.D., Independent Director
- Rebecca M. Henderson Ph.D., Independent Director
- Daniel M. Junius, Independent Director
Who owns IDEXX Laboratories stock?
IDEXX Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional investors include APG Asset Management N.V. (0.25%), Robeco Institutional Asset Management B.V. (0.18%), Harvey Investment Co. LLC (0.12%), Wendell David Associates Inc. (0.04%), Bath Savings Trust Co (0.04%) and Denali Advisors LLC (0.03%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.
Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?
IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc., Harvey Investment Co. LLC, State Treasurer State of Michigan, Winslow Evans & Crocker Inc., Wendell David Associates Inc., Bath Savings Trust Co and Mutual of America Capital Management LLC. Company insiders that have sold IDEXX Laboratories stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.
Who bought IDEXX Laboratories stock? Who is buying IDEXX Laboratories stock?
IDEXX Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Denali Advisors LLC, Robeco Institutional Asset Management B.V., Wealth Enhancement Advisory Services LLC, Hermes Investment Management Ltd., Oakbrook Investments LLC and LS Investment Advisors LLC. View Insider Buying and Selling for IDEXX Laboratories.
How do I buy IDEXX Laboratories stock?
Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IDEXX Laboratories' stock price today?
MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of IDEXX Laboratories stock can currently be purchased for approximately $164.71.
Consensus Ratings for IDEXX Laboratories (NASDAQ:IDXX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 4 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.33)|
|Consensus Price Target: ||$171.60 (4.18% upside)|Consensus Price Target History for IDEXX Laboratories (NASDAQ:IDXX)
Analysts' Ratings History for IDEXX Laboratories (NASDAQ:IDXX)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/6/2017||Canaccord Genuity||Reiterated Rating||Buy||$180.00||N/A|
|8/23/2017||Bank of America Corporation||Upgrade||Neutral -> Buy||$175.00||Low|
|8/21/2017||Stifel Nicolaus||Reiterated Rating||Buy||$185.00||Low|
|7/28/2017||CL King||Upgrade||Neutral -> Buy||$200.00||Medium|
|2/3/2017||Feltl & Co.||Downgrade||Hold -> Sell||N/A|
|8/3/2016||Northcoast Research||Upgrade||Sell -> Neutral||N/A|
|4/13/2016||Credit Suisse Group||Boost Price Target||Outperform||$80.00 -> $85.00||N/A|
|2/1/2016||Piper Jaffray Companies||Reiterated Rating||Neutral||$73.00 -> $75.00||N/A|
|1/31/2016||William Blair||Reiterated Rating||Outperform||N/A|
Earnings History for IDEXX Laboratories (NASDAQ:IDXX)Earnings History by Quarter for IDEXX Laboratories (NASDAQ IDXX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/1/2017||Q2 2017||$0.85||$0.95||$502.44 million||$508.90 million||View||Listen|
|4/28/2017||Q1 17||$0.61||$0.77||$455.10 million||$462.00 million||View||N/A|
|2/2/2017||Q416||$0.51||$0.58||$436.07 million||$443.00 million||View||Listen|
|11/1/2016||Q316||$0.59||$0.62||$448.60 million||$448.30 million||View||Listen|
|8/2/2016||Q216||$0.62||$0.74||$444.83 million||$467.00 million||View||Listen|
|4/29/2016||Q116||$0.47||$0.51||$403.48 million||$417.55 million||View||Listen|
|1/29/2016||Q415||$0.44||$0.48||$397.39 million||$400.00 million||View||Listen|
|10/28/2015||Q315||$0.53||$0.54||$409.33 million||$406.00 million||View||Listen|
|7/30/2015||Q215||$0.57||$0.60||$412.57 million||$413.30 million||View||Listen|
|4/28/2015||Q115||$0.98||$0.98||$394.38 million||$382.00 million||View||N/A|
|1/30/2015||Q414||$0.80||$0.95||$373.20 million||$352.00 million||View||N/A|
|10/24/2014||Q314||$0.90||$1.05||$371.80 million||$384.00 million||View||Listen|
|7/25/2014||Q214||$1.06||$1.10||$385.20 million||$390.00 million||View||N/A|
|4/25/2014||Q114||$0.87||$0.89||$361.58 million||$360.20 million||View||Listen|
|2/4/2014||Q413||$0.81||$0.82||$347.08 million||$354.10 million||View||N/A|
|10/22/2013||Q313||$0.83||$0.86||$339.70 million||$338.30 million||View||N/A|
|7/23/2013||Q2 2013||$0.97||$0.99||$356.80 million||$352.60 million||View||N/A|
|4/23/2013||Q1 2013||$0.83||$0.81||$341.06 million||$332.10 million||View||N/A|
|1/29/2013||Q4 2012||$0.71||$0.78||$325.10 million||$319.50 million||View||N/A|
Earnings Estimates for IDEXX Laboratories (NASDAQ:IDXX)
2017 EPS Consensus Estimate: $2.88
2018 EPS Consensus Estimate: $3.53
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for IDEXX Laboratories (NASDAQ:IDXX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for IDEXX Laboratories (NASDAQ:IDXX)
Insider Ownership Percentage: 2.77%Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership Percentage: 87.58%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/28/2017||Jonathan W Ayers||Chairman||Sell||13,000||$150.79||$1,960,270.00|| |
|8/23/2017||Rebecca M Henderson||Director||Sell||5,156||$153.29||$790,363.24|| |
|8/22/2017||Rebecca M Henderson||Director||Sell||2,578||$152.86||$394,073.08|| |
|8/16/2017||Jonathan W Ayers||Chairman||Sell||58,000||$155.00||$8,990,000.00|| |
|8/15/2017||Jonathan W Ayers||CEO||Sell||20,000||$154.62||$3,092,400.00|| |
|8/14/2017||Jonathan W Ayers||CEO||Sell||18,000||$154.91||$2,788,380.00|| |
|8/9/2017||Jonathan W Ayers||Chairman||Sell||17,000||$154.54||$2,627,180.00|| |
|8/8/2017||Jonathan W. Ayers||Chairman||Sell||18,000||$155.22||$2,793,960.00|| |
|8/3/2017||Lawrence D Kingsley||Director||Buy||2,000||$151.76||$303,520.00|| |
|5/31/2017||Giovani Twigge||Insider||Sell||2,572||$166.90||$429,266.80|| |
|5/30/2017||Jonathan W Ayers||Chairman||Sell||13,000||$167.82||$2,181,660.00|| |
|5/22/2017||William T End||Director||Sell||5,000||$162.55||$812,750.00|| |
|5/10/2017||Jonathan W Ayers||Chairman||Sell||27,000||$162.69||$4,392,630.00|| |
|5/5/2017||Jonathan W. Ayers||Chairman||Sell||26,000||$160.61||$4,175,860.00|| |
|5/4/2017||Rebecca M Henderson||Director||Sell||1,700||$159.95||$271,915.00|| |
|3/1/2017||Lawrence D Kingsley||Director||Buy||1,000||$146.48||$146,480.00|| |
|2/22/2017||Jonathan W Ayers||Chairman||Sell||35,000||$142.58||$4,990,300.00|| |
|2/8/2017||Brian P Mckeon||VP||Sell||9,924||$141.64||$1,405,635.36|| |
|2/8/2017||Daniel M Junius||Director||Sell||3,000||$141.75||$425,250.00|| |
|2/8/2017||Jonathan W. Ayers||Chairman||Sell||36,250||$141.63||$5,134,087.50|| |
|11/29/2016||Jonathan W Ayers||Chairman||Sell||27,424||$119.77||$3,284,572.48|| |
|11/28/2016||Jonathan W Ayers||CEO||Sell||13,188||$119.57||$1,576,889.16|| |
|11/23/2016||Thomas Craig||Director||Sell||8,500||$120.06||$1,020,510.00|| |
|11/9/2016||Jonathan W. Ayers||Chairman||Sell||40,000||$107.85||$4,314,000.00|| |
|11/8/2016||William T End||Director||Sell||5,000||$109.87||$549,350.00|| |
|8/25/2016||Rebecca M Henderson||Director||Sell||9,924||$110.43||$1,095,907.32|| |
|8/15/2016||Barry C Johnson||Director||Sell||9,924||$111.37||$1,105,235.88|| |
|8/8/2016||Michael J. Phd Williams||Insider||Sell||49,560||$108.94||$5,399,066.40|| |
|8/5/2016||William T End||Director||Sell||5,000||$108.50||$542,500.00|| |
|8/4/2016||Jonathan W. Ayers||Chairman||Sell||60,000||$107.69||$6,461,400.00|| |
|5/5/2016||William T End||Director||Sell||4,924||$85.87||$422,823.88|| |
|2/24/2016||Michael J Phd Williams||EVP||Sell||2,000||$71.93||$143,860.00|| |
|2/9/2016||Thomas Craig||Director||Sell||2,054||$69.52||$142,794.08|| |
|2/8/2016||Brian P. Mckeon||CFO||Sell||9,054||$69.65||$630,611.10|| |
|11/30/2015||Thomas Craig||Director||Sell||7,000||$70.28||$491,960.00|| |
|11/12/2015||Rebecca M. Henderson||Director||Sell||2,300||$68.39||$157,297.00|| |
|8/31/2015||Thomas Craig||Director||Sell||800||$71.77||$57,416.00|| |
|8/18/2015||Michael J. Phd Williams||EVP||Sell||6,586||$78.34||$515,947.24|| |
|8/18/2015||Thomas Craig||Director||Sell||2,900||$79.41||$230,289.00|| |
|8/17/2015||Jonathan W Ayers||CEO||Sell||14,799||$78.45||$1,160,981.55|| |
|5/18/2015||William T End||Director||Sell||3,527||$134.51||$474,416.77|| |
|3/10/2015||William T End||Director||Sell||3,500||$150.89||$528,115.00|| |
|3/4/2015||Johnny D Powers||EVP||Sell||6,168||$158.49||$977,566.32|| |
|2/17/2015||Brian P Mckeon||CFO||Sell||5,000||$156.99||$784,950.00|| |
|2/12/2015||Jonathan W Ayers||CEO||Sell||58,245||$155.45||$9,054,185.25|| |
|2/5/2015||Rebecca M Henderson||Director||Sell||2,934||$156.27||$458,496.18|| |
|2/4/2015||Thomas Craig||Director||Sell||2,200||$157.02||$345,444.00|| |
|1/14/2015||Jonathan W Ayers||CEO||Sell||28,512||$157.68||$4,495,772.16|| |
|12/3/2014||Jonathan W Ayers||CEO||Sell||29,000||$148.49||$4,306,210.00|| |
|11/13/2014||Thomas Craig||Director||Sell||5,000||$152.45||$762,250.00|| |
|11/5/2014||Jonathan W Ayers||CEO||Sell||29,000||$143.45||$4,160,050.00|| |
|11/4/2014||Johnny D Powers||EVP||Sell||1,292||$142.70||$184,368.40|| |
|8/13/2014||M Anne Szostak||Director||Buy||2,000||$127.03||$254,060.00|| |
|2/20/2014||M Anne Szostak||Director||Buy||2,000||$126.71||$253,420.00|| |
|2/19/2014||Thomas Craig||Director||Sell||4,800||$125.42||$602,016.00|| |
|2/3/2014||Jonathan Ayers||CEO||Sell||81,294||$112.46||$9,142,323.24|| |
|11/26/2013||Jonathan Ayers||CEO||Sell||78,178||$105.29||$8,231,361.62|| |
|11/22/2013||Sophie Vandebroek||Director||Buy||1,000||$107.84||$107,840.00|| |
|11/13/2013||Jonathan Ayers||CEO||Sell||78,178||$106.36||$8,315,012.08|| |
|11/4/2013||M Anne Szostak||Director||Buy||1,000||$108.24||$108,240.00|| |
|11/4/2013||Michael Phd Williams||EVP||Sell||6,020||$108.19||$651,303.80|| |
|10/31/2013||William T End||Director||Sell||2,500||$108.32||$270,800.00|| |
|10/25/2013||Jonathan W Ayers||CEO||Sell||78,178||$104.36||$8,158,656.08|| |
|9/13/2013||Johnny Powers||EVP||Sell||13,128||$96.59||$1,268,033.52|| |
|9/5/2013||Michael J Phd Williams||EVP||Sell||5,162||$95.58||$493,383.96|| |
|5/9/2013||Ali Naqui||VP||Sell||12,961||$87.00||$1,127,607.00|| |
|2/4/2013||Merilee Raines||CFO||Sell||175,929||$94.25||$16,581,308.25|| |
|11/13/2012||Jonathan W Ayers||CEO||Sell||15,000||$89.92||$1,348,800.00|| |
|9/5/2012||Johnny D Powers||EVP||Sell||4,000||$97.12||$388,480.00|| |
|8/8/2012||Merilee Raines||CFO||Sell||7,726||$88.84||$686,377.84|| |
Headline Trends for IDEXX Laboratories (NASDAQ:IDXX)
Latest Headlines for IDEXX Laboratories (NASDAQ:IDXX)
Loading headlines, please wait.
IDEXX Laboratories (IDXX) Chart for Sunday, October, 22, 2017